BioMerieux SA

BIM: XPAR (FRA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
&C?LOCK|N%LmBLOCK|lYx!pWT

BioMérieux: Sequential Acceleration Aided by US Tailwinds; Near-Term Outlook Cautious

BioMérieux's organic sales growth accelerated sequentially to 8% in the third quarter, driven by nonrespiratory panels, microbiology, and industrial applications. Management reconfirmed its full-year guidance, sending shares up by about 4% at market open on Nov. 3.

Sponsor Center